other material
confidence high
sentiment positive
materiality 0.65
HOOKIPA reports HB-200 + pembro 53% ORR in CPS≥20; Phase 2/3 to start Q4 2024
HOOKIPA Pharma Inc.
- Updated data from 42 first-line HPV16+ HNSCC patients: ORR 53%, CR 18%, DCR 82% in CPS≥20 subgroup.
- Median follow-up 5.6 months; grade ≥3 TRAEs in 14% of patients, no treatment-related deaths.
- Neoadjuvant HB-200 + chemo showed deep responses in 81% (17/21) of HPV16+ oropharyngeal cancer patients.
- HB-700 preclinical data induced KRAS mutation-specific T cell responses; Phase I planned for KRAS-mutated cancers.